Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Signs Distribution Deal for its Tests in the Philippines

NEW YORK (GenomeWeb) – Biocept said today that it has made a preferred provider agreement with Harle Group subsidiary HarlePhil Ventures to market and distribute the company's Target Selector liquid biopsy assays in the Republic of the Philippines. 

Under the terms of the agreement, Biocept will still perform all diagnostic testing in its San Diego-based CLIA lab. HarlePhil will be responsible for sales, marketing, and distribution, and for managing reimbursements in the Philippines.  Additional terms of the transaction were not disclosed.

The deal is Biocept's first in Southeast Asia. It now has three international distribution partnerships, including two other agreements inked this year in Israel and Mexico.

The firm also anticipates expanding into additional international markets, President and CEO Michael Nall said in a statement. 

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.